2024 SABCS会议预告｜12月12日有哪些精彩看点？

地点和时间：Hemisfair Ballroom 1-2，12月12日 7:00 – 8:30 am

主持人：Lisa Carey, Lineberger Comprehensive Cancer Center University of North Carolina

PS2-01: 达尔西利与安慰剂联合来曲唑或阿那曲唑作为HR+/HER2-晚期乳腺癌女性患者的一线治疗：Ⅲ期DAWNA-2试验中预设的PFS最终分析

Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial.

徐兵河 中国医学科学院肿瘤医院

PS2-02: Tibremciclib（BPI-16350）或安慰剂联合氟维司群治疗内分泌治疗后进展的HR阳性/HER2阴性晚期乳腺癌患者：Ⅲ期研究的更新分析

Tibremciclib (BPI-16350) plus fulvestrant versus placebo plus fulvestrant for patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: Updated analysis of the phase III study.

胡夕春 复旦大学附属肿瘤医院

PS2-03: Comparative overall survival of CDK4/6is plus an aromatase inhibitor (AI) in HR+/HER2- MBC in the US real-world setting.

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS2-04: Health related quality of life with first- versus second-line CDK4/6 inhibitor use in advanced breast cancer: results from the phase 3 SONIA trial (BOOG 2017-03).

Noor Wortelboer, Erasmus University Medical Center, Rotterdam, Netherlands

PS2-05: PRESERVE 2: A randomized, phase 3, double-blind trial of trilaciclib or placebo in patients (pts) receiving first-line gemcitabine/carboplatin (GCb) for locally advanced or metastatic triple-negative breast cancer (mTNBC).

Shom Goel, University of Melbourne Peter MacCallum Cancer Centre, Melbourne, Australia

PS2-06: 一线瑞波西利联合内分泌治疗（ET）与联合化疗在临床浸润性HR阳性/HER2阴性晚期乳腺癌患者中的比较：基于内在亚型、基因和标志物表达的RIGHT Choice研究亚组分析

First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression.

卢彦伸 中国台湾大学医学院附属医院

PS2-07: Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive/HER2-Negative  Metastatic Breast Cancer (MBC).

Francesco Schettini, Hospital Clinic Barcelona, Barcelona, Spain

PS2-08: Association of MammaPrint® with gene expression pathways predictive of resistance to cyclin-dependent kinase inhibition.

Adam Brufsky, University of Pittsburgh, Pittsburgh, Pennsylvania

PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial.

Guilherme Nader-Marta, Dana-Farber Cancer Institute, New York, New York

PS2-10: 整合ctDNA和肿瘤分数特征在解读晚期HR阳性转移性乳腺癌患者对内分泌治疗和CDK4/6抑制剂的分子反应和耐药机制中的应用

Integrating ctDNA and Tumor Fraction Features for Deciphering Molecular Response and Resistance Mechanism to Endocrine Therapy and CDK4/6 Inhibition in Advanced HR-positive Metastatic Breast Cancer.

Hao Liao 北京大学肿瘤医院

• 7:30-7:45 Discussant (PS2-01, PS2-02, PS2-03, PS2-04, PS2-05)

CDK4/6抑制剂

CDK 4/6i

Kari Wiskinski, University of Wisconsin School of Medicine and Public Health, Madison,

Wisconsin

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS2-06, PS2-07, PS2-08, PS2-09, PS2-10)

生物标志物

Biomarkers

Matthew Goetz, Mayo Clinic, Rochester, Minnesota

• 8:15-8:30 Panel Q&A

地点和时间：Room 221ABC，12月12日 7:00 – 8:30 am

主持人：Mylin Torres, Winshop Cancer Institute of Emory University

PS6-01: The PARP inhibitor rucaparib is a strong radiosensitizer in women with residual triple-negative breast cancer treated concurrently with adjuvant radiotherapy.

Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York

PS6-02: Association of VMAT versus 3D-CRT Radiotherapy Treatment Technique with Acute Toxicity of Regional Nodal Irradiation: A Secondary Analysis of the SAPHIRe Phase III Randomized Clinical Trial.

Chelain Goodman, MD Anderson Cancer Center, Houston, Texas

PS6-03: Post-Mastectomy Proton Therapy Imparts Increased Risk of Capsular Contracture in Reconstructed Breast Cancer Patients.

Mehmet Murat Zerey, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida

PS6-04: Eliminating breast surgery for invasive, hormone-positive breast cancers with an exceptional response to endocrine therapy and ablative radiotherapy: a single-arm, phase 2 trial.

Simona Shaitelman, MD Anderson Cancer Center, Houston, Texas

PS6-05: First report of clinicopathologic characteristics and surgical outcomes of patients in the Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy (ASLAN) trial (KBCSG-28).

Han-Byoel Lee, Seoul National University College of Medicine, Seoul, South Korea

PS6-06: Upstage of N-Stage by Diagnostic Axillary Lymph Node Dissection in Patients w/ Isolated Tumor Cells or Micrometastases in Sentinel/Target Lymph Node after Neoadjuvant Chemotherapy - Results from the Prospective Multicenter AXSANA / EUBREAST 3 Study.

Thorsten Kuehn, University of Ulm, Germany

PS6-07: Clinical and patient reported outcomes in women offered oncoplastic breast conserving surgery as an alternative to mastectomy: 12-month results of the UK ANTHEM multicentre prospective cohort study.

Shelley Potter, University of Bristol Medical School, Bristol, United Kingdom

PS6-08: Quality of life following total mastectomy, breast-conserving surgery, and immediate breast reconstruction in patients with breast cancer: A multicenter cross-sectional study.

Hirohito Seki, Kyorin University School of Medicine, Mikita, Japan

• 7:30-7:45 Discussant (PS6-01, PS6-02, PS6-03, PS6-04)

放射肿瘤学

Radiation Oncology

Erin Gillespie, University of Washington, Seattle, Washington

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS6-05, PS6-06, PS6-07, PS6-08)

生物标志物

Biomarkers

Alastair Thompson, Baylor College of Medicine, Houston, Texas

• 8:15-8:30 Panel Q&A

地点和时间：Stars at Night 1-2，12月12日 7:00 – 8:30 am

主持人：Ian Krop, Yale School of Medicine

PS8-01: ZN-1041，一种潜在的同类最佳BBB穿透性HER2抑制剂，在乳腺癌脑转移患者中具有很高的抗肿瘤活性

ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases.

Ethan (Di) Zhu, ZionPharma, Shanghai, China

PS8-02: 评估TL938在HER2阳性晚期实体瘤患者中的安全性、有效性和药代动力学的一项Ⅰ期研究

A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors.

Xiaoyang Xia, Wuhan Institute of Technology, Wuhan, China

PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03).

William Jacot, Montpellier Cancer Institute and University of Montpellier, Montpellier, France

PS8-04: Targeting clinically advanced breast cancer with conjugated and unconjugated HER2 antibodies: Does copy number matter?

Nicole Odzer, Yale School of Medicine, New Haven, Connecticut

PS8-05: ACE-Breast-08：一种新型抗HER2-ADC ARX788，在TKI经治的HER2阳性晚期乳腺癌患者中的Ⅰ期研究

ACE-Breast-08: a phase I study of ARX788, a novel anti-HER2 antibody-drug conjugate, in patients with TKI pretreated HER2 positive advanced breast cancer.

王晓稼 浙江省肿瘤医院

PS8-06: 维迪西妥单抗（一种抗HER2单克隆抗体-MMAE偶联物）与拉帕替尼联合卡培他滨在HER2阳性晚期乳腺癌伴肝转移患者中的疗效：一项随机、开放标签的Ⅲ期研究

A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis.

王佳玉 中国医学科学院肿瘤医院

PS8-07: GQ1005（一种有潜力的HER2-ADC）在转移性HER2阳性乳腺癌患者中的疗效和安全性研究

Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer.

王碧芸 复旦大学附属肿瘤医院

PS8-08: SHR-A1811，一种抗HER2-ADC，在391例经过大量预处理的HER2表达或突变的多发性实体瘤患者中的疗效和安全性：一项全球性、多中心、首例人体、Ⅰ期研究

Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study.

姚和瑞 中山大学孙逸仙纪念医院

PS8-09: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study.

Alberto Montero, University Hospitals Cleveland Medical Center, Cleveland, Ohio

• 7:30-7:45 Discussant (PS8-01, PS8-02, PS8-03,PS8-04)

放射肿瘤学

Radiation Oncology

Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS8-05, PS8-06, PS8-07, PS8-08, PS8-09)

生物标志物

Biomarkers

Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

• 8:15-8:30 Panel Q&A

地点和时间： Stars at Night 3-4，12月12日 7:00 – 8:30 am 

主持人：Charles Perou, Lineberger Comprehensive Cancer Center University of North Carolina

PS9-01: Actionable Genomic Alterations in Localized Hormone Receptor Positive (HR+) Breast Cancer and Impact on Clinical Outcomes: Results from Comprehensive Whole Exome Sequencing (WES) and Tumor-Informed circulating tumor DNA (ctDNA) analysis.

Marla Lipsyc-Sharf, UCLA Health, Santa Monica, California

PS9-02: Serial circulating tumor DNA (ctDNA) assessment to predict treatment response and identify genomic evolution in patients with metastatic breast cancer (mBC).

Laura Linville, Johns Hopkins Kimmel Cancer Center, Washington, D.C.

PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study.

Eleanor Taranto, University of Pennsylvania, Philadelphia, Pennsylvania

PS9-04: Evaluating racial genomic differences in de novo metastatic breast cancer utilizing ctDNA: results from a large multi-center consortium.

Emily Podany, Washington University School of Medicine, St. Louis, Missouri

PS9-05: Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer.

Mitchell Elliott, University of Toronto, Toronto, Canada

PS9-06: Tracking structural variants in ctDNA using a high-sensitivity assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

Hervé Bonnefoi, Bordeaux Institute of Oncology, Bordeaux, France

PS9-07: Epigenomic Characterization of ER Transcriptional Activation via Liquid Biopsy.

Jonathan Beagan, Precede Biosciences, Boston, Massachusetts

PS9-08: Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC).

Albert Grinshpun, Dana-Farber Cancer Institute, Boston, Massachusetts

• 7:30-7:45 Discussant (PS9-01, PS9-02, PS9-03, PS9-04)

评估微小残留病变

Evaluating Minimal Residual Disease

Yara Abdou, University of North Carolina School of Medicine, Chapel Hill, NorthCarolina

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS9-05, PS9-06, PS6-07, PS9-08)

ctDNA在肿瘤进化中的作用

ctDNA in tumor evolution

Marija Balic, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania

• 8:15-8:30 Panel Q&A

地点和时间：Room 221ABC，12月12日 7:00 – 8:30 am

主持人：Lindsay Peterson, Washington University Siteman Cancer Center, St. Louis, Missouri

PS15-01: Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.

Margaux Wooster, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York

PS15-02: Genome-wide association study (GWAS) of aromatase inhibitor musculoskeletal toxicity (AIMT) among early-stage breast cancer (BC) survivors.

Pietro Lapidari, Institut de Cancérologie Gustave Roussy, Villejuif, France

PS15-03: Retrospective study of GLP-1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes

Jasmine Sukumar, MD Anderson Cancer Center, Houston, Texas

PS15-04: Impact of a dietitian and nurse-led survivorship clinic utilizing ePRO collection on body composition and muscle strength in early-stage breast cancer: Results from the Linking You to Support and Advice (LYSA) Randomized Control Trial.

Katie E. Johnston, University College Cork, Cork, Ireland

PS15-05: Breast Cancer Patients with High-Risk Disease Characteristics have Proportionately Higher Risk of Mortality from Non-Breast Cancer Related Causes in both Non-Metastatic and Metastatic Disease.

Varsha Gupta, Roswell Park Comprehensive Cancer Center, Buffalo, New York

PS15-06: Ability to comply with placebo predicts overall survival in randomized trial.

Tara Sanft, Yale School of Medicine, New Haven, Connecticut

PS15-07: Late effects of chemotherapy on patient-reported falls among older breast cancer survivors.

Inimfon Jackson, MD Anderson Cancer Center, Houston, Texas

PS15-08: Factors and trends associated with alcohol intake in late survivorship for patients with breast cancer.

Sanjna Rajput, Mayo Clinic, Rochester, Minnesota

• 7:30-7:45 Discussant (PS15-01, PS15-02, PS15-03, PS15-04)

体重和生物标志物

Weight and Biomarkers

Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York

• 7:45-8:00 Panel Q&A

• 8:00-8:15 Discussant (PS15-05, PS15-06, PS15-07, PS15-08)

生存预测因子

Predictors of Survival

Tara Sanft, Yale University, New Haven, Connecticut

• 8:15-8:30 Panel Q&A

地点和时间：Hall 1，12月12日 8:30 – 9:00 am

主持人：Virginia Kaklamani, UT Health Mays Cancer Center, San Antonio, Texas

解析癌症结果中种族差异的社会和生物驱动因素的巨大挑战

The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes

Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia

地点和时间：Hall 1，12月12日 9:00 – 11:45 am

主持人：Michael Gnant, Medical University of Vienna, Vienna, Austria, and Zhi-Ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China

GS2-01: Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

Icro Meattini, University of Florence, Florence, Italy

GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial

Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina

GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators.

Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland

GS2-04: Discussant about GS2-01, 02, and 03

Elinor Sawyer, King’s College London, London, United Kingdom

GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).

Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina

GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).

Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts

GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.

Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany

GS2-08: Discussant Puneet Singh, MD Anderson Cancer Center, Houston, Texas

GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.

Hongchao Pan, University of Oxford, Oxford, United Kingdom

GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer.

Mikael Eriksson, Karolinska Institutet, Solna, Sweden

GS2-11: APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.

Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York

地点和时间：Hall 1，12月12日 12:00– 12:50 pm

主持人：Carlos Arteaga, UT Southwestern, Dallas, Texas

RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.

Judy Boughey, Mayo Clinic, Rochester, Minnesota

RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.

Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH

RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).

Steffi Hartmann, University of Rostock, Rostock, Germany

RF2-04: Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO).

Melanie Machiels, Universiteit Antwerpen, Antwerp, Belgium

RF2-05: Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.

Demet Özcan, Aarhus University Hospital, Aarhus, Denmark

RF2-06: A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.

Luke Peppone, University of Rochester Medical Center, Rochester, New York

地点和时间：Halls 2-3，12月12日 12:30 – 2:00 pm

壁报专场3详细日程见链接https://rs-os-lyh-dt-publicread-file-bosmetadata-prod.liangyihui.net/boss-upload/Pk2oYdrR4WV1r_x1EKnesQ/5PzHmLarHZxPHHfI.pdf

地点和时间：Stars at Night 3-4，12月12日 12:30 – 1:45 pm

主持人：Claudine Isaacs, Georgetown University, Washington, DC
Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia

基于饱和基因组编辑的BRCA2中VUS的功能和临床分类

Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2

Fergus Couch, Mayo Clinic, Rochester, Minnesota

风险预测模型的更新

Updates on Risk Prediction Models

Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom

对治疗响应的BRCA1/2中的逆转突变

Reversion Mutations in BRCA1/2 in Response to Therapy 

Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

• Panel Discussion

地点：Advocacy Lounge, Room 220

地点和时间：Stars at Night 1-2，12月12日 1:00 – 1:50 pm

主持人：Phillipe Afthimos, Insitut Jules Bordet, Brussels, Belgium

Dara Aisner, University of Colorado Medical School, Aurora, Colorado

Jorge Reis-Filho, AstraZeneca, Gaithersburg, Maryland

Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada

Jenna Canzoniero, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland

Bob Riter, Cornell University, Ithaca, New York

地点和时间：Stars at Night 1-2，12月12日 2:00 – 3:00 pm

主持人：Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York

ER阳性疾病中腋窝分期的省略：数据是什么？

Omission of Axillary Staging in ER+ Disease What is The Data?

Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts

ER阳性疾病中腋窝分期的省略：对放疗的影响

Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy

Jean Wright, UNC School of Medicine, Chapel Hill, North Carolina

ER阳性疾病中腋窝分期的省略：对辅助全身治疗的影响

Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy

Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

pCR后的放疗

Radiation Post pCR

Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana

• Panel Discussion

地点和时间：Stars at Night 1-2，12月12日 2:00 – 3:00 pm

主持人：Fred Howard, University of Chicago, Chicago, Illinois

病理学

Pathology

Kun-Hsing Yu, Harvard University, Cambridge, Massachusetts

影像学和筛查

Imaging and Screening

Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands

药物发现、深度学习和大数据管理

Drug Discovery, Deep Learning, and Large Data Management 

Erika Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee• Panel Discussion

• Panel Discussion

地点和时间：Stars at Night 1-2，12月12日 3:00 – 3:30 pm

主持人：Luisa Arispe, Northwestern University Feinberg School of Medicine, Chicago, Illinois

讲者：Steffi Oesterreich, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania

地点和时间：Stars at Night 3-4，12月12日 3:30 – 5:15 pm

主持人：Debra Patt, Texas Oncology-Austin Central, Austin, Texas

Patient Advocate: Kay Firth-Butterfield, Austin, Texas

风险与机遇

Hazards and Opportunities

Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts

超越Chat GPT：医疗领域的生成式AI

Beyond Chat GPT: Generative AI in Healthcare 

Ian Maurer, Genomoncology, Cleveland, Ohio

临床实践中的数字工具

Digital Tools for Clinical Practice

Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

• Panel Discussion

地点和时间：Stars at Night 1-2，12月12日 3:30 – 5:15 pm

主持人：Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

早期ER阳性乳腺癌中的免疫治疗

Immunotherapy in Early ER Positive Breast Cancer 

Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland

三阴性乳腺癌（TNBC）治疗的优化

Optimization of Treatment in TNBC

Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

免疫治疗的未来

The Future of Immunotherapy 

Evanthia Roussos Torres, University of Southern California, Los Angeles, California

• Panel Discussion

地点和时间：Hemisfair Ballroom 3，12月12日 3:30 – 5:15 pm

主持人：Mina Sedrak, UCLA David Geffen School of Medicine, Los Angeles, California

Patient Advocate: Sandi Stanford, San Antonio, Texas

生物学 - 激素变化下的衰老免疫系统

Biology - the Aging Immune System with Hormonal Changes 

Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut

定义和避免低价值外科治疗

Defining and Avoiding Low Value Surgical Therapy 

Christina Minami, Brigham and Women's Hospital, New York City

全身治疗

Systemic Therapies

Hans Wildiers, University Hospital Leuven, Leuven, Belgium

• Panel Discussion

地点和时间：Hemisfair Ballroom 1-2，12月12日 3:30 – 5:15 pm

主持人：Heide Ford, University of Colorado Denver School of Medicine, Denver, Colorado

Patient Advocate: Christine Hodgdon, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

脑转移

Brain Metastases

Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado

肝转移

Liver Metastases 

Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium

骨转移

Bone Metastases

Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee

• Panel Discussion

地点和时间：Hemisfair Ballroom 3，12月12日 5:30 – 7:00 pm

主持人：Banu Arun, MD Anderson Cancer Center, Houston, Texas

PS16-01: Longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors.

Timothy Simmons, Freeman Hospital Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

PS16-02: Polygenic risk score as an aid for risk stratification in benign breast disease.

Kush Lohani, Mayo Clinic, Rochester, Minnesota

PS16-03: Isoform-level analyses of breast cancer and its subtypes uncover extensive genetic risk mechanisms undetected at the gene-level.

Taylor Head, Bhattacharya Lab for Computational Genomics, Houston, Texas

PS16-04: Differences in breast cancer phenotype by germline TP53 variant functional classification.

Renata Sandoval, Dana-Farber Cancer Institute, New York, New York

PS16-05: Primary breast cancer prevention using oral endoxifen.

Per Hall, Karolinska Institutet, Stockholm, Sweden

PS16-07: Quantitative breast density measures and radiomic parenchymal phenotypes improve breast cancer risk prediction among Black and White women undergoing mammography screening.

Anne Marie McCarthy, University of Pennsylvania, Philadelphia, Pennsylvania

PS16-08: Trends in LCIS Incidence from 2000-2020 Mirror USPSTF Screening Guidelines: A SEER Registry Analysis.

Anna C. Beck, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

PS16-09: A decision support intervention to promote the use of preventive therapy among women at high risk for invasive breast cancer.

Inimfon Jackson, MD Anderson Cancer Center, Houston, Texas

• 6:00-6:15 Discussant (PS16-01, PS16-02, PS16-03, PS16-04, PS16-05)

遗传和多基因乳腺癌风险

Genetic and Polygenetic Risk for Breast Cancer

Fergus Couch, Mayo Clinic, Rochester, Minnesota

• 6:15-6:30 Panel Q&A

• 6:30-6:45 Discussant (PS16-07, PS16-08, PS16-09)

高风险筛查和预防的当代方法

Contemporary approaches to high-risk screening and prevention

Sonya Reid, Vanderbilt University Medical Center, Nashville, Tennessee

• 6:45-7:00 Panel Q&A

地点和时间：Stars at Night 1-2，12月12日 5:30 – 7:00 pm

主持人：Hope Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center

PS17-01: Spatial transcriptomics identifies molecular patterns predictive of response to neoadjuvant chemotherapy in triple-negative breast cancer.

Isobelle Wall, King’s College, London, United Kingdom

PS17-02: Molecular and Immune Landscape of Metaplastic Triple Negative Breast Cancer Compared with Invasive Ductal Triple Negative Breast Cancer.

Pooja Advani, Mayo Clinic, Jacksonville, Florida

PS17-03: Real World Adjuvant Capecitabine Utilization and Patient Outcomes Among Patients With Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.

Ava Strahan, Ohio State University Stover Lab for Clinical Computational Oncology, Columbus, Ohio

PS17-04: Implications of Adjuvant Chemotherapy in Small Triple-Negative Breast Cancer.

Hannah Hackbart, Cedar-Sinai Hospital, Beverly Hills, California.

PS17-05: Use and benefit of neoadjuvant versus adjuvant chemotherapy in node-negative, T1 triple negative breast cancer.

Jesus Anampa, Albert Einstein College of Medicine, New York, New York

PS17-06: Neutrophil-to-lymphocyte ratio (NLR) predicts long-term survival in early triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT).

Gabriel Polho, Instituto do Câncer do Estado de São Paulo – ICESP, São Paulo, Brazil

PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial.

Hans-Christian Kolberg, Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany

PS17-08: Association of antibiotic exposure with pathologic complete response in patients with non-metastatic triple-negative breast cancer receiving neoadjuvant chemotherapy and pembrolizumab.

Alexis Espinal, University of Michigan Medical School, Ann Arbor, Michigan

PS17-09: Immune landscape and clinical features of acquired resistance to immune checkpoint blockade in triple negative breast cancer.

Veerle Geurts, Netherlands Cancer Institute, Amsterdam, Netherlands

PS17-10: Genomic and transcriptomic analyses of residual invasive triple-neg breast cancer after neoadjuvant chemotherapy in prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab + capecitabine versus capecitabine; KCSG-BR18-21).

Seock-Ah Im, Seoul National University Hospital, Seoul, South Korea

• 6:00-6:15 Discussant (PS17-01, PS17-02, PS17-03, PS17-04, PS17-05)

主题1

Topic 1

Filipa Lynce, Dana-Farber Cancer Institute, Boston, Massachusetts

• 6:15-6:30 Panel Q&A

• 6:30-6:45 Discussant (PS17-06, PS17-07, PS17-08, PS17-09, PS17-10)

主题2

Topic 2

Rita Nanda, University of Chicago, Chicago, Illinois

• 6:45-7:00 Panel Q&A

地点和时间：Stars at Night 3-4，12月12日 5:30 – 7:00 pm

主持人：Kokmal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

PS18-01: Spatial Transcriptomics-Derived Classification of Invasive Lobular Carcinoma: Associations with Clinical, Genomic Characteristics, and Prognosis.

Matteo Serra, Institut Jules Bordet, Brussels, Belgium

PS18-02: E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma.

Lounes Djerroudi, Institut Curie, Paris, France

PS18-03: GeoMx DSP and CosMx single cell spatial transcriptomics for molecular characterization of invasive lobular breast cancer cells and their microenvironment.

Lynda Bennett, UT Southwestern Medical Center, Dallas, Texas

PS18-04: Tumor intrinsic and extrinsic characteristics of invasive lobular carcinomas.

Lise Mangiante, Stanford Cancer Center, Palo Alto, California

PS18-05: Clinical Management and Oncological Outcomes of Pure Pleomorphic and Florid Lobular Carcinoma in Situ of the Breast: Results from the MultiLCIS Study.

Massimo Ferrucci, Veneto Institute of Oncology, Padua, Italy.

PS18-06: Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma.

Rinath Jeselsohn, Dana-Farber Cancer Institute, Boston, Massachusetts

PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamide.

Jennifer Richer, University of Colorado School of Medicine, Aurora, Colorado

PS18-08: MDA iLobulaRx: An Advanced Clinico-Patho-Therapeutic Tool for Risk Stratification in Early-Stage Invasive Lobular Carcinoma.

Jason Mouabbi, MD Anderson Cancer Center, Houston, Texas

PS18-09: Endocrine Response in Women with Invasive Lobular Carcinoma (TBCRC 037): A Multicenter Randomized Clinical Tria9.

Priscilla McAuliffe, University of Pittsburgh, Pittsburgh, Pennsylvania

• 6:00-6:15 Discussant (PS18-01, PS18-02, PS18-03, PS18-04)

小叶乳腺癌的转化研究主题

Translational topics in Lobular Breast Cancer

Christos Sotirou, Institut Jules Bordet, Brussels, Belgium

• 6:15-6:30 Panel Q&A

• 6:30-6:45 Discussant (PS18-05, PS18-06, PS18-07, PS18-08, PS18-09)

提高临床结果

Advancing Clinical Outcomes

Rita Mukhtar, University of California San Francisco, San Francisco, California

• 6:45-7:00 Panel Q&A

地点和时间：Hemisfair Ballroom 1-2，12月12日 5:30 – 7:00 pm

主持人：Debra Pratt, Cleveland Clinic, Cleveland, Ohio

PS19-01: Medication Nonadherence and Financial Toxicity Among Patients with Metastatic Breast Cancer on Cyclin Dependent Kinase 4/6 Inhibitors.

Claire Sathe, Columbia University Herbert Irving Comprehensive Cancer Center

PS19-02: Economic Impact of Concurrent Tissue and Circulating Tumor DNA Molecular Profiling In Advanced Breast Cancer Patients

Zach Rivers, Tempus AI, Burlington, Vermont

PS19-03: Contemporary patterns of Medicare Utilization and Spending on Herceptin and its Biosimilars in Breast Cancer.

Charmi Bhanushali, Saint Vincent Hospital, Worcester, Massachusetts

PS19-04: Exploring the broad societal value of pembrolizumab in triple-negative breast cancer in Canada.

Kate Young, Royal Marsden Hospital, London, United Kingdom

• 6:00-6:15 Discussant

经济毒性

Financial Toxicity

Stephen Schleicher, Tennessee Oncology, Nashville, Tennessee

• 6:15-6:30 Panel Q&A

地点和时间：Halls 2-3，12月12日 5:30 – 7:00 pm

壁报专场4详细日程见链接https://rs-os-lyh-dt-publicread-file-bosmetadata-prod.liangyihui.net/boss-upload/Pk2oYdrR4WV1r_x1EKnesQ/fA5LwGb0BJEmAa27.pdf

时间：12月12日 8:00  – 10:30 pm

Texas Ballroom, Grand Hyatt San Antonio Hotel

本文整理自SABCS官网公布的信息，不代表名单为实际现场参会专家。若有任何遗漏或错误，可联系我们进行修改。